# Clinical and Medical Datasets for CapoAI Drug Discovery
## REAL MEDICAL DATA - ZERO SYNTHETIC SUBSTITUTES

### FDA-Approved Drug Datasets

#### 1. FDA Orange Book Database
**Source**: https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
**Content**: All FDA-approved drugs with therapeutic equivalence
**Size**: ~40,000+ approved drug products
**Required Fields**:
- **Active Ingredient**: Chemical name and strength
- **Dosage Form**: Tablet, capsule, injection, etc.
- **Route of Administration**: Oral, IV, topical, etc.
- **Therapeutic Equivalence**: AB, AN, AP, etc. ratings
- **Approval Date**: FDA approval timestamp
- **Patent Expiration**: Exclusivity data
- **NDC Numbers**: National Drug Code identifiers

#### 2. DrugBank Complete Dataset
**Source**: https://go.drugbank.com/ (Academic license required)
**Size**: 14,000+ drug entries with molecular data
**Critical Fields**:
- **Drug Structure**: SMILES, InChI, SDF molecular representations
- **Pharmacokinetics**: ADME properties (Absorption, Distribution, Metabolism, Excretion)
- **Target Interactions**: Protein targets with binding affinities
- **Side Effects**: Adverse drug reaction profiles
- **Contraindications**: Drug-drug interaction warnings
- **Bioavailability**: F% values for different formulations
- **Half-life**: t₁/₂ values in hours
- **Protein Binding**: % plasma protein bound

#### 3. ChEMBL Bioactivity Database
**Source**: https://www.ebi.ac.uk/chembl/
**Size**: 2.3M+ compounds, 15M+ bioactivities
**Essential Data**:
- **IC50 Values**: Half-maximal inhibitory concentrations (nM)
- **Ki Values**: Inhibition constants (nM)
- **Kd Values**: Dissociation constants (nM)
- **EC50 Values**: Half-maximal effective concentrations
- **Selectivity Ratios**: Target specificity measurements
- **Cell Line Data**: Activity in specific cancer/disease cell lines
- **Animal Model Results**: In vivo efficacy data
- **Assay Conditions**: pH, temperature, buffer conditions

### Clinical Trial Datasets

#### 4. ClinicalTrials.gov Database
**Source**: https://clinicaltrials.gov/api/
**Content**: 400,000+ clinical studies worldwide
**Required Extractions**:
- **Primary Endpoints**: Efficacy measurements
- **Secondary Endpoints**: Safety and biomarker data  
- **Patient Demographics**: Age, gender, disease stage
- **Dosing Regimens**: mg/kg, timing, duration
- **Adverse Events**: Frequency and severity (CTCAE grades)
- **Response Rates**: Complete response, partial response, stable disease
- **Survival Data**: Overall survival, progression-free survival
- **Biomarkers**: Predictive and prognostic indicators

#### 5. FDA Adverse Event Reporting System (FAERS)
**Source**: https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html
**Purpose**: Post-market drug safety surveillance
**Critical Fields**:
- **MedDRA Terms**: Standardized adverse event terminology
- **Reporting Rates**: Events per patient-year exposure
- **Severity Scores**: Life-threatening, hospitalization, death
- **Temporal Relationships**: Time to onset post-drug administration
- **Dose-Response**: Relationship between dose and AE frequency
- **Rechallenge Data**: AE recurrence upon re-exposure

### Disease-Specific Datasets

#### 6. Cancer Genome Atlas (TCGA)
**Source**: https://portal.gdc.cancer.gov/
**Size**: 20,000+ tumor samples across 33 cancer types
**Required Data**:
- **Mutation Profiles**: Somatic mutations, copy number variations
- **Expression Data**: RNA-seq, miRNA-seq quantification
- **Methylation**: CpG island methylation status
- **Survival Outcomes**: Overall survival, disease-free survival
- **Treatment Response**: Chemotherapy, radiation, targeted therapy response
- **Tumor Stage/Grade**: TNM staging, histologic grade
- **Molecular Subtypes**: PAM50, consensus clustering results

#### 7. Alzheimer's Disease Neuroimaging Initiative (ADNI)
**Source**: http://adni.loni.usc.edu/
**Content**: Longitudinal AD biomarker and cognitive data
**Essential Measurements**:
- **CSF Biomarkers**: Aβ₄₂, tau, p-tau levels (pg/mL)
- **PET Imaging**: Amyloid PET, tau PET SUV ratios
- **Cognitive Scores**: MMSE, ADAS-Cog, CDR-SOB
- **MRI Volumes**: Hippocampal, entorhinal cortex volumes
- **Genetic Data**: APOE genotype, GWAS variants
- **Progression Rates**: Annual cognitive decline slopes

#### 8. UK Biobank
**Source**: https://www.ukbiobank.ac.uk/
**Size**: 500,000+ participants with deep phenotyping
**Multi-omics Data**:
- **Genomics**: Whole genome sequencing, SNP arrays
- **Proteomics**: SOMAscan protein measurements
- **Metabolomics**: NMR and MS metabolite profiles
- **Electronic Health Records**: ICD-10 diagnosis codes
- **Imaging**: MRI brain, cardiac, abdominal imaging
- **Lifestyle Factors**: Diet, exercise, smoking history

### Pharmacokinetic/Pharmacodynamic Datasets

#### 9. Population PK/PD Models
**Sources**: Literature + FDA drug labels
**Required Parameters**:
- **Clearance**: CL (L/h) population estimates
- **Volume of Distribution**: Vd (L) steady-state values  
- **Absorption Rate**: ka (h⁻¹) first-order constants
- **Bioavailability**: F (fraction) oral/IV ratios
- **Inter-individual Variability**: CV% for PK parameters
- **Covariate Effects**: Age, weight, renal/hepatic function
- **Drug-Drug Interactions**: CYP enzyme inhibition/induction

#### 10. Therapeutic Drug Monitoring Data
**Sources**: Hospital laboratory databases
**Concentration-Response Relationships**:
- **Therapeutic Ranges**: Minimum effective concentrations
- **Toxic Thresholds**: Concentrations causing adverse effects
- **Protein Binding**: Free fraction measurements
- **Active Metabolites**: Concentrations and activity
- **Tissue Distribution**: CSF, tumor, intracellular levels

### Real-World Evidence Datasets

#### 11. Insurance Claims Databases
**Sources**: 
- MarketScan (IBM)
- Optum Clinformatics
- Medicare/Medicaid claims
**Healthcare Utilization Data**:
- **Prescription Patterns**: Drug utilization rates
- **Healthcare Costs**: Total cost of care
- **Hospitalization**: Admission rates, length of stay
- **Comorbidities**: Charlson comorbidity index
- **Treatment Pathways**: Sequence of therapies
- **Adherence Metrics**: Medication possession ratios

### Quality Assurance Requirements

#### Data Validation Pipeline
```rust
struct MedicalDataValidator {
    fda_orange_book: FDADatabase,
    drugbank: DrugBankData,
    chembl: ChEMBLBioactivity,
    clinical_trials: ClinicalTrialsDatabase,
    tcga: CancerGenomeData,
}

impl MedicalDataValidator {
    fn validate_drug_efficacy_data(&self) -> ValidationReport {
        // Cross-reference FDA approvals with clinical trial results
        // Verify IC50 values across multiple assays
        // Confirm molecular structures match approved formulations
        // NO synthetic or simulated efficacy data
    }
    
    fn validate_safety_profiles(&self) -> SafetyValidationReport {
        // Cross-validate FAERS data with clinical trial AEs
        // Confirm dose-response relationships
        // Verify temporal relationships for causality
        // NO estimated or modeled safety profiles
    }
    
    fn compute_real_world_effectiveness(&self) -> RealWorldEvidence {
        // Analyze insurance claims outcomes
        // Measure actual therapeutic responses
        // Calculate number needed to treat (NNT)
        // NO simulated population responses
    }
}
```

### Regulatory Compliance
- **HIPAA**: All patient data must be de-identified
- **21 CFR Part 11**: FDA electronic records compliance
- **GDPR**: European patient data protection
- **Good Clinical Practice**: Data integrity standards

### Data Integration Standards
- **FAIR Principles**: Findable, Accessible, Interoperable, Reusable
- **OMOP Common Data Model**: Observational health data standardization
- **HL7 FHIR**: Healthcare information exchange standards
- **CDISC**: Clinical data interchange standards

**CRITICAL**: Every dataset must have documented provenance, validation against multiple independent sources, and statistical power calculations to ensure clinical relevance.